To recover your password please fill in your email address
Please fill in below form to create an account with us
A randomised phase 2 trial of 177Lu-PSMA617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer (ANZUP1603).
See ANZCTR for full trial details >
To determine the activity and safety of Lu-PSMA vs cabazitaxel in patients with castration resistant prostate cancer.
Prostate Cancer Foundation Australia (PCFA), Endocyte, Australian Nuclear Science and Technology Organisation (ANSTO)
Men with castration resistant prostate cancer suitable for chemotherapy with cabazitaxel (surgical or medical castration, and previous chemotherapy with docetaxel).
Australian Lead Group:
Prof Michael Hofman